Collectively, our study uncovers a novel oncogenic role of the CDK4/6‐DUB3 pathway, which promotes YAP1 stabilization and tumor‐promoting function, highlighting that targeting CDK4/6 offers a potential therapeutic strategy for CRC with aberrantly upregulated DUB3 and YAP1. This evidence concerns the gene CDK4 and neoplasm.